409
Participants
Start Date
October 31, 2012
Primary Completion Date
May 31, 2015
Study Completion Date
January 31, 2016
Tralokinumab
Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
Tralokinumab
Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
Placebo
Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
Research Site, Phoenix
Research Site, La Jolla
Research Site, Sacramento
Research Site, Tampa
Research Site, Winter Park
Research Site, Atlanta
Research Site, Honolulu
Research Site, Chicago
Research Site, Louisville
Research Site, Ann Arbor
Research Site, Rochester
Research Site, Chesterfield
Research Site, Summit
Research Site, Durham
Research Site, Hershey
Research Site, Philadelphia
Research Site, Charleston
Research Site, Nashville
Research Site, McAllen
Research Site, McKinney
Research Site, Salt Lake City
Research Site, Box Hill
Research Site, Camperdown
Research Site, Concord
Research Site, Darlinghurst
Research Site, Frankston
Research Site, Glen Osmond
Research Site, New Lambton
Research Site, Parkville
Research Site, Prahran
Research Site, Woodville South
Research Site, Edmonton
Research Site, Vancouver
Research Site, Windsor
Research Site, Montreal
Research Site, Québec
Research Site, Ashkelon
Research Site, Haifa
Research Site, Jerusalem
Research Site, Petah Tikva
Research Site, Rehovot
Research Site, Tel Aviv
Research Site, Lima
Research Site, Lima Cercado
Research Site, Seoul
Lead Sponsor
MedImmune LLC
INDUSTRY